Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9503312 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2CD69ELANECYP2C19HPGD | |
| SCHEMBL10197363 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2CD69ELANEGABRA1GABRB2 | |
| SCHEMBL18120698 | 0.82 | SOD1 (0.51) | SMN1; SMN2CYP2C19KDM4ECYP2C9POLB | |
| SCHEMBL8219820 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2MAOBCYP2C19RAB9AALDH1A1 | |
| SCHEMBL17896578 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2CD69ELANECYP2C19HPGD | |
| SCHEMBL852266 | 0.75 | GABRA1 (0.46) | SMN1; SMN2CD69ELANEGABRA1GABRB2 | |
| SCHEMBL16133043 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2CD69ELANECYP2C19HPGD | |
| SCHEMBL17896563 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2CD69ELANECYP2C19HPGD | |
| SCHEMBL14488840 | 0.74 | CYP3A4 (0.47) | SMN1; SMN2ELANEGABRA1GABRB2KDM4E | |
| SCHEMBL8778112 | 0.74 | HPGD (0.54) | SMN1; SMN2CYP2C19RAB9AHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | SMN1; SMN2 456/4885CD69 4395/4885ELANE 524/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | SMN1; SMN2 456/4885CD69 4395/4885ELANE 524/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | SMN1; SMN2 1020/4885CD69 4489/4885ELANE 116/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | SMN1; SMN2 3985/4885CD69 4032/4885ELANE 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.